We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Neurology

Younger adults with intracerebral hemorrhage have better outcomes but distinct risk profile: INTERACT3 sub-analysis

MedXY Editorial Team•Jul 26, 2026•Neurology
Intracerebral HemorrhageYoung AdultsstrokeINTERACT3age differences


Graphical Abstract
  • Approximately 19% of ICH patients in the INTERACT3 trial were ≤50 years old.

  • Younger patients had larger hematoma volumes but significantly lower 6-month mortality (9.1% vs 16.6%; adjusted OR 0.42) and reduced disability.

  • A significant age-by-treatment interaction suggested younger patients benefited more from the bundled care intervention.

  • Younger patients reported better quality of life across mobility, self-care, and usual activities.

  • Distinct risk profile: higher rates of smoking, alcohol use, male predominance, and higher BMI in younger group.

Study snapshot

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Stroke and Systemic Embolism Following Atrial Fibrillation Ablation: Insights from the EMBOL-AF Global Registry and Contemporary EvidenceThe EMBOL-AF Global Registry provides comprehensive data on stroke and systemic embolism post-atrial fibrillation ablation, highlighting incidence, timing, risk factors, and procedural impacts alongside evolving ablation strategies and longSep 27, 2026Retinal OCTA as a Window into Cerebral Small Vessel Disease and Cognitive Decline Post-StrokeThis longitudinal study shows that retinal microvascular changes measured by OCTA correspond with cerebral small vessel disease progression and cognitive decline in mild ischemic stroke patients, highlighting OCTA’s potential as a nonSep 21, 2026Early Recanalization in Distal and Medium Vessel Occlusion Strokes: Tenecteplase vs AlteplaseIn patients with distal and medium vessel occlusion strokes, tenecteplase achieves higher early recanalization rates and reduces early infarct growth compared to alteplase, supporting its preferential use in this clinical setting.Sep 15, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Cilostazol Therapy in Intracerebral Hemorrhage: Enhancing Dural Lymphatic Function for Neuroprotection
Cilostazol promotes dural lymphatic remodeling and hematoma clearance post-ICH without increasing bleeding risk, representing a promising therapeutic strategy to improve neurological outcomes.
Sep 6, 2026
Evaluating Tirofiban Plus Aspirin in Branch Atheromatous Disease Stroke: Insights from the STRATEGY TrialThe STRATEGY trial assessed whether combining tirofiban with aspirin improves outcomes in branch atheromatous disease (BAD)-related stroke but found no significant benefit over aspirin alone in preventing neurological deterioration or recurSep 5, 2026
Immunogenicity and Safety of Pentavalent Meningococcal MenABCWY Vaccine in Adolescents and Young Adults: Integrated Evidence from Late-Phase Clinical TrialsThis review synthesizes phase 2 and 3 trial data demonstrating that the pentavalent MenABCWY vaccine is immunologically non-inferior and well tolerated compared with MenB-fHbp and MenACWY-CRM vaccines, offering a simplified, effective vacciSep 4, 2026